Home Bausch + Lomb Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative...

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Bausch + Lomb announced that Ophthalmology and Therapy has published results from a phase 3 study which assessed the efficacy and safety of LUMIFY Preservative Free redness reliever eye drops compared to LUMIFY redness reliever eye drops for reducing ocular redness.

“Since launching in 2018, LUMIFY has been the No. 1 doctor-recommended redness reliever brand, known for delivering noticeable results in one minute and lasting up to eight hours,”1 said John Ferris, president, Consumer, Bausch + Lomb. “This study demonstrates that our new LUMIFY Preservative Free eye drops reduce redness quickly and are just as safe and effective as the original LUMIFY, providing a needed option for patients with eye sensitivities.”

In the randomized, active-controlled, multicenter study, 380 participants with ocular redness received either LUMIFY Preservative Free or LUMIFY, administered as a single drop four times daily for four weeks. The primary objective was to demonstrate that LUMIFY Preservative Free is non-inferior to LUMIFY in reducing ocular redness. The primary efficacy endpoint was investigator-assessed ocular redness score at eight timepoints from five-minutes to 240-minutes after drop administration on day one. The secondary objective of the study was to compare the safety of LUMIFY Preservative Free and LUMIFY.

The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. A day one analysis of all 11 time points (one minute to 480 minutes post-administration) further supported these findings; and additional secondary efficacy endpoint data from one minute, 360 minutes and 480 minutes post-administration demonstrated that LUMIFY Preservative Free performs similarly to LUMIFY. The overall safety profile of LUMIFY Preservative Free was favorable and comparable to LUMIFY, and the occurrence of ocular treatment-emergent adverse events was similar in both treatment groups. In this clinical trial, LUMIFY Preservative Free demonstrated to have a low incidence of side effects, like rebound redness and loss of efficacy over time, when used as directed.

“The results show that LUMIFY Preservative Free is a well-tolerated alternative option for consumers with ocular redness who have sensitivities to preservatives or are at increased risk of ocular surface disease,” said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, Tennessee.

For more information on LUMIFY Preservative Free, click here.

 

REFERENCES

  1. IQVIA, Average Share of Weekly Doctor Recommendations, Jan – Dec 2024.

 

Read more news from WO here.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

- Advertisment -

Most Popular

CooperVision Expands Professional Affairs Team

CooperVision has strengthened its U.S. Professional Affairs team with three new team members and two leadership promotions. The appointments include: Eric Harris, OD, FAAO, joins...

A Natural Extension of Care: How Two Optometrists Built Aesthetics Into Their Practices

For Kelsey Grounds, OD, FAAO, and Courtney Walters, OD, aesthetics did not begin as a separate business line so much as an outgrowth of...

Want to Be Featured in WO’s 2026 Holiday Gift Guide?

It’s almost gifting season, and Women In Optometry is getting ready for its annual Holiday Gift Guide! Each year, WO highlights female makers, creators and...

We’re “Falling” for These Practice Accent Colors

As the leaves begin to change, we’re highlighting four optometry offices with color palettes we’re “falling” for. From rich greens to earthy neutrals and bold...